HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Packard, C. J. Articles by Shepherd, J. Search for Related Content PubMed PubMed Citation Articles by Packard, C. J. Articles by Shepherd, J. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol 27, 930-938, Copyright © 1986 by Lipid Research, Inc.

ARTICLES

Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects

CJ Packard, RJ Clegg, MH Dominiczak, AR Lorimer and J Shepherd

This study was designed to investigate the response of Type III hyperlipoproteinemic subjects to bezafibrate therapy. The metabolism of apolipoprotein B was examined in four lipoprotein subclasses of Sf 60- 400 (large very low density lipoprotein (VLDL)), Sf 20-60 (small VLDL), Sf 12-20 (intermediate density lipoprotein (IDL)), and Sf 0-12 (low density lipoprotein (LDL)) before and during bezafibrate therapy. Treatment reduced the plasma concentration of VLDL and raised high density lipoprotein (HDL) cholesterol. There was no net change in LDL cholesterol or its associated apolipoprotein B. The decrease in plasma VLDL derived mainly from an inhibition of synthesis of both large and small subfractions which reduced the number of particles in the circulation without normalizing their lipid composition. Catabolism of the larger VLDL also increased, presumably as a result of lipoprotein lipase activation. Although the plasma concentration of LDL was unchanged, both its synthesis and catabolism were perturbed. Its fractional catabolic rate fell by 50%, but the impact that this would have had on its steady state level in the circulation was apparently blunted by a decrease in its synthesis from Sf 12-20 IDL. In the control phase of the study, most IDL apolipoprotein B was converted to LDL. Bezafibrate therapy channelled this material towards direct catabolism.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. F. Watts, P. H. R. Barrett, J. Ji, A. P. Serone, D. C. Chan, K. D. Croft, F. Loehrer, and A. G. Johnson Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome Diabetes, March 1, 2003; 52(3): 803 - 811. [Abstract] [Full Text] [PDF]

				H. A. Ardern, G. M. Benson, K. E. Suckling, M. J. Caslake, J. Shepherd, and C. J. Packard Apolipoprotein B overproduction by the perfused liver of the St. Thomas' mixed hyperlipidemic (SMHL) rabbit J. Lipid Res., December 1, 1999; 40(12): 2234 - 2243. [Abstract] [Full Text] [PDF]

				C. J. Packard and J. Shepherd Lipoprotein Heterogeneity and Apolipoprotein B Metabolism Arterioscler. Thromb. Vasc. Biol., December 1, 1997; 17(12): 3542 - 3556. [Abstract] [Full Text]

				M. Bertolotti, M. Concari, P. Loria, N. Abate, A. Pinetti, M. E. Guicciardi, and N. Carulli Effects of Different Phenotypes of Hyperlipoproteinemia and of Treatment With Fibric Acid Derivatives on the Rates of Cholesterol 7{alpha}-Hydroxylation in Humans Arterioscler. Thromb. Vasc. Biol., August 1, 1995; 15(8): 1064 - 1069. [Abstract] [Full Text]